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Cellular-state information between generations of
developing cells may be propagated via regulatory
regions. We report consistent patterns of gain and
loss of DNase I-hypersensitive sites (DHSs) as cells
progress from embryonic stem cells (ESCs) to termi-
nal fates. DHS patterns alone convey rich information
about cell fate and lineage relationships distinct
from information conveyed by gene expression.
Developing cells share a proportion of their DHS
landscapes with ESCs; that proportion decreases
continuously in each cell type as differentiation
progresses, providing a quantitative benchmark of
developmental maturity. Developmentally stable
DHSs densely encode binding sites for transcription
factors involved in autoregulatory feedback circuits.
In contrast to normal cells, cancer cells extensively
reactivate silenced ESC DHSs and those from devel-
opmental programs external to the cell lineage from
which the malignancy derives. Our results point to
changes in regulatory DNA landscapes as quantita-
tive indicators of cell-fate transitions, lineage rela-
tionships, and dysfunction.
INTRODUCTION
Under natural conditions, tissue and cellular differentiation along
defined lineages is characterized by an inexorably forward-mov-888 Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc.ing process that terminates in highly specialized cells. Wadding-
ton, followingMorgan (Morgan, 1901), characterized the process
of development as essentially ‘‘epigenetic’’ (from ‘‘epigenesis’’)
(Waddington, 1939) and also introduced the metaphor of an
‘‘epigenetic landscape’’ (Waddington, 1940), which he depicted
with a ball rolling down a hill of bifurcating valleys symbolizing the
specification of defined cell lineages and fates during the prog-
ress of differentiation (Waddington, 1939, 1957). It is notable
that Waddington’s usage of epigenetic to denote the origination
and propagation of information about cellular states during dif-
ferentiation differs considerably from its recent reformulation to
mean ‘‘on the genome’’ and its association with chemical mod-
ifications to DNA or chromatin (Ptashne, 2007). Here we employ
the classical usage throughout.
Waddington astutely reasoned that epigenesis is a ‘‘histori-
cal’’ process requiring a memory ‘‘faculty’’ to keep directed line-
age programs on track (Waddington, 1939). Indeed, developing
cells are frequently exposed to stimuli, whether exogenous
(e.g., a morphogen) or endogenous (e.g., a transcription factor
[TF]), that can permanently alter cellular fate. Whether or in
what form cells in fact maintain information concerning prior
developmental fate decisions during epigenesis is currently
unknown.
The epigenetic landscape paradigm has also been invoked to
explain abnormal processes such as oncogenesis (Pujadas and
Feinberg, 2012). Cancer cells are widely described as being ‘‘de-
differentiated’’ compared with their normal counterparts, based
on limited analyses of metabolic (Warburg, 1956), histological
(Gleason and Mellinger, 1974), gene-activity (Hirszfeld et al.,
1932; Tatarinov, 1964), and proliferative and self-renewal pheno-
types (Beard, 1902; Waddington, 1935). However, quantifying
this concept and generalizing it beyond a few selected markers
have proven difficult.
Chromatin structure represents a highly plastic vehicle
for specifying cellular regulatory states and is a conceptually
attractive template for recording and transmitting epigenetic in-
formation (Bernstein et al., 2006; Hawkins et al., 2010; Paige
et al., 2012; Wamstad et al., 2012; Zhu et al., 2013). DNase
I-hypersensitive sites (DHSs) represent focal alterations in the
primary structure of chromatin that result from engagement of
sequence-specific transcription factors in place of a canonical
nucleosome (Gross and Garrard, 1988; Thurman et al., 2012).
In a classic experiment, Groudine and Weintraub demonstrated
that induced DHSs could be propagated to, and stably perpetu-
ated by, daughter cells even after the inducing stimulus had been
withdrawn (Groudine and Weintraub, 1982). This result suggests
that newly arising DHSs created by TF occupancy of quiescent
regulatory DNA have the potential to encode cellular states
and to perpetuate that information through continued TF occu-
pancy in daughter cells. Whether, or to what extent, such a
mechanism operates during normal development and differenti-
ation, however, is currently unknown.
To explore the role of TF-driven chromatin structure at regu-
latory DNA in normal and transformed cells during epigenesis,
we analyzed genome-wide patterns of DHSs across a wide
array of cell types and states, including definitive adult primary
cells, embryonic stem cells (ESCs), cells undergoing directed
lineage differentiation from ESCs to cardiomyocytes, and
diverse cancer cell types. Our findings, detailed below, are inter-
preted to indicate four fundamental conclusions. First, patterns
of DHSs in definitive cells encode ‘‘memory’’ of early develop-
mental fate decisions that establish lineage hierarchies. Second,
lineage differentiation couples the extensive activation of novel
regulatory DNA compartments with propagation and sequential
restriction of the ES DHS landscape as a function of cellular
maturity. Third, developmentally stable DHSs chiefly encode
binding sites for self-regulating TFs, suggesting a mechanistic
role for TF-encoded feedback circuits in propagating develop-
mental information. Finally, oncogenesis is accompanied by a
disordered retrograde remodeling of the regulatory DNA land-
scape in a fashion that defies normal developmental pathways
and departs fundamentally from the paradigm of the epigenetic
landscape. Together these findings indicate a central role for
patterning and propagation of regulatory DNA marked by
DHSs in the genesis and proper maintenance of developmental
programs.
RESULTS
Lineage Programming of Human Regulatory DNA
Regulatory DNA landscapes defined by DHSs are both highly
cell type specific and highly stable (Thurman et al., 2012).We first
sought to determine how the regulatory landscapes of diverse
definitive cells were related to one another and to the regulatory
DNA of ESCs. To address this, we collected genome-wide maps
of DHSs from human ESCs plus 38 diverse normal definitive pri-
mary cell types (Thurman et al., 2012) for which anatomical and
histological origins could be unambiguously verified. To expand
the phenotypic range of cell types and to deepen coverage ofthe well-characterized hematopoietic lineage, we obtained nine
additional definitive cell samples from adult donors, including
B cells (CD19+, CD20+), natural killer (NK) cells (CD56+), CD34+
hematopoietic progenitors (three separate donors), and skin ker-
atinocytes (three donors). The relative representation of different
major embryological lineages (mesoderm, ectoderm, endoderm)
among these 49 cell types parallels that of recognized cell types
(Bard et al., 2005), of which those ofmesodermal origin comprise
the significant majority. We performed DNase I-hypersensitivity
mapping on each of the 49 cell types using a common protocol
and delineated DHSs using a common algorithm that has been
extensively validated for both sensitivity and specificity (John
et al., 2011; Thurman et al., 2012) (Experimental Procedures),
resulting in an average of 161,160 autosomal DHSs per cell
type (at false discovery rate [FDR] 1%, range 91,720 to
257,172; Table S1). Although most DHSs were highly cell selec-
tive, preliminary inspection of the DNase I profiles suggested
systematic commonalities between major cell-type groups (Fig-
ures 1A, S1A, and S1B).
To visualize these relationships quantitatively, we considered
each DHS to be either present or absent within a given cell type
(versus total DNase I signal, to avoid biasing toward promoters,
which display higher average DNase I sensitivity than distal ele-
ments) (Thurman et al., 2012) and computed the Euclidean dis-
tance between all nonredundant pairs of cell types. Rendering
the results with simple unsupervised nearest-neighbor clustering
(Figure 1B) produced an ab initio dendrogram that recapitulated
known cell-lineage relationships with remarkable detail, as well
as broader features of embryological origin. On a gross level,
ESCs occupied the deepest root, and derivatives of the three
germ layers (mesoderm, ectoderm, and endoderm) were
correctly partitioned into separate high-level clusters (Figure 1B).
Mesodermal progenywere further partitioned intoparaxialmeso-
derm, primitive mesoderm, and hemangioblast derivatives. The
common embryological origin of endothelia and blood was
clearly represented, aswas thefinepartitioningof thehematopoi-
etic tree into hematopoietic progenitors, lymphoid and myeloid
cells, and the different subtypes of lymphoid tissue, including B
cells, T cells, NK cells, and more primitive lymphoblastoid cells.
Although relationships between the derivatives of paraxial meso-
dermare lesswell understood,weobserved subgroups thatwere
organized into anatomical units, such as grouping of heart and
great vessel stroma. The distinctiveness of these major cluster
groups was clearly evinced by displaying the aforementioned
pairwise Euclidean distance measures with a three-dimensional
principal coordinate analysis (PCoA) (Figure 1C). This analysis
also revealed that the regulatory DNA landscape of ESCs oc-
cupies a central position relative to all other cell types.
Toconfirm the robustnessof the clustering,weperformedboot-
strap analysis, which determined the nearly complete stability of
all major branches (Figure S1C). The robustness of the clustered
cell relationshipswas further attestedby thestrict cohesionofmul-
tiple samples of the same cell type, including gingival fibroblasts
(n = 2), cardiac fibroblasts (n = 2), hematopoietic progenitors
(n = 3), and keratinocytes (n = 3), that were derived from different
individuals at different times. In addition, we prospectively tested
the ability of the dendrogram to classify eight additional cell types
of diverse embryological origin (Figures S1D–S1F). Importantly,Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc. 889
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clustering gene-expression patterns for the same cell types failed
to recover the fundamental lineage-branching relationships
exposed by clustering DHS patterns (Figures S3A and S3B),
including rootingof the lineage tree inESCs, andshowed improper
high-level segregationofgerm-layerderivativesand improperpar-
titioning of mesodermal derivatives. These results demonstrate
that the dendrogram in Figure 1B is not driven by functional
convergence on gene-expression patterns.
The fact that the aforementioned lineage relationships—
including representation of specific primitive commitment
events—can be derived from a simple clustering of the DHS
landscapes of terminally differentiated cells suggests that the
linear patterning of regulatory DNA along the genome encodes
an imprint of prior cellular fate decisions. Given that ESCs repre-
sent a common developmental ancestor to the other cell types,
the centrality of ESCs within the PCoA plot suggests that signif-
icant yet distinct components of the ESC regulatory landscape
are shared in each of the definitive cell types (see below).
An ‘‘Hourglass’’ Pattern of Conservation
at Developmental Regulatory DNA
Next, we sought to determine whether the pattern of develop-
mental maturity reflected in the dendrogram was systematically
paralleled by patterns of evolutionary constraint on regulatory
DNA. We first identified regulatory DNA stably arising at seven
distinct inferred developmental branch points (epiblast, meso-
derm, hemangioblast, paraxial mesoderm, endothelia, hemato-
poietic, and lymphoid) by identifying DHSs common to the
corresponding dependent branches of the dendrogram in
Figure 1. We then used phyloP to calculate the mean level of
evolutionary constraint for each set of elements (Experimental
Procedures). This analysis revealed that regulatory DNA com-
mon to mesodermal derivatives (and thus inferred to be stably
arising during the onset of the mesodermal lineage) is signifi-
cantly more evolutionarily constrained than that arising during
either early embryogenesis or later lineage differentiation (Fig-
ure 1D). This pattern is compatible with the ‘‘hourglass’’ model
of development (Duboule, 1994; Raff, 1996) that has been varia-
bly described using cross-speciesmorphology (Von Baer, 1828),
gene expression (Kalinka et al., 2010), and gene conservation
(Domazet-Loso and Tautz, 2010).
Developmental Persistence of Chromatin Accessibility
at Primitive Enhancers
We next asked whether enhancers active during early develop-
ment could be persistently marked by DHSs in definitive cells.Figure 1. Lineage Programming of Human Regulatory DNA
(A)Evidence of lineage patterning in primary DHS data. DNase I cleavage-density p
region along chromosome 9. Cell types are colored according to their embryolog
(B)Clustering DHS profiles recovers precise embryological relationships. Unbiased
plus ESCs. Branches and cell types are colored according to their embryological o
the right. Note the rooting of the tree by ESCs and the partitioning of major branch
fate decisions such as partitioning of hemangioblast derivatives into endothelia a
(C)PCoA of cell-type relationships. Shown is each cell type from (B) projected into
above. Note the centrality of ESCs and the spatial separation of major lineage g
(D) ‘‘Hourglass’’ pattern of regulatory DNA conservation across the development
DHSs common to the indicated lineage branches. Error bars represent 95% con
See also Figure S1 and S3 and Tables S1 and S2.Systematic studies of evolutionarily conserved human DNA ele-
ments in transgenic mice have identified >700 early develop-
mental enhancers (Pennacchio et al., 2006), each of which
displays consistent activity in one or more embryonic tissues
(Figure 2A). Of 721 nonpromoter human enhancers with repro-
ducible tissue-staining patterns in transgenic day 11.5 embryos,
a surprising proportion—64%—exhibit DNase I hypersensitivity
in at least one definitive human cell type (Figure 2B). To quantify
the tissue activity spectra of these elements, we systematically
collated images of enhancer-driven lacZ expression in individual
transgenic animals and related these with cross-cell-type pat-
terns of DNase I hypersensitivity at the same elements in defini-
tive cells. For example, an enhancer that is selectively active in
embryonic heart tissue (Figure 2A, 1st image) is DNase I hyper-
sensitive selectively within cells derived from human heart and
great vessel structures (Figure 2C), and an enhancer that is
selectively active in embryonic blood vessels (Figure 2A, 3rd
image) is DNase I hypersensitive selectively within hemangio-
blast derivatives (endothelia and hematopoietic progenitors; Fig-
ure 2C). By contrast, an enhancer with extremely broad tissue
activity (Figure 2A, 4th image) is DNase I hypersensitive in nearly
all definitive cell types (Figure 2C).
These findings generalize across the spectrum of enhancers:
100% of enhancers active in embryonic blood vessels are found
to be DNase I hypersensitive in adult endothelial cells, whereas
only 30% of all other embryonic enhancers are DNase I hyper-
sensitive in endothelia (Figures S2A–S2C). Similarly, 73% of
enhancers that are active in embryonic heart tissue are DNase
I hypersensitive within cells derived from human heart and great
vessel structures, whereas only 27% of all other embryonic
enhancers are DNase I hypersensitive in these cell types
(Figure S2D).
We also found striking correlation between the number of
primitive tissues in which enhancer activity was detected and
the number of definitive cell types in which a DHS was detected
at that enhancer (Figure 2D). Together, these results suggest
both systematic developmental persistence of DNase I hyper-
sensitivity at a subset of early developmental enhancers and a
persistent imprint of enhancer functional spectra in the form of
DHS patterning across different definitive cell types.
Restriction versus Expansion of the Chromatin
Landscape during Differentiation
The relationship between ESCs and definitive lineage derivatives
in Figure 1, combined with evidence for developmental persis-
tence of individual DHSs, prompted us to analyze in detail therofiles for 24 exemplary primary human cell types and ESCs across an350 kb
ical derivation as indicated in (B).
clustering of the linear patterning of DHSs from 48 diverse, definitive cell types
rigin, with embryological ancestors common tomultiple cell types indicated on
es corresponding to the trilaminar embryo. Note also the demarcation of early
nd blood.
a three-dimensional principal coordinates space. Cell-type coloring is indicated
roups.
al spectrum. Shown is the mean evolutionary conservation (phyloP, x axis) of
fidence intervals.
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Figure 2. Developmental Persistence of Chromatin Accessibility at Primitive Enhancers
(A) Mouse day 11.5 embryonic tissue activity (blue lacZ staining) of five representative transgenic human enhancer elements from the VISTA database. Shown
below each image are numbers of individual embryos with enhancer activity (staining) in the indicated anatomical structure.
(B) Persistence of DNase I hypersensitivity at embryonic enhancers. The percentage of embryonic enhancers from the VISTA database marked with DHSs in one
or more definitive cell types (top) or early human fetal tissues (day 70–150) (bottom).
(C) DNase I hypersensitivity at five enhancer elements corresponding to (A) across 47 definitive cell types from Figure 1. Note the relationship between the
anatomical staining patterns in (A) and the cellular restriction (or lack thereof) of DNase I hypersensitivity.
(D) Embryonic enhancer tissue spectrum parallels DHS spectrum in definitive cells. The number of embryonic tissues with an active enhancer by lacZ staining
(x axis) is linearly proportional (linear regression p value < 103) to the number of definitive cell types showing DNase I hypersensitivity at the same enhancer
(y axis).
See also Figure S2.
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relative gain and loss of DHSs along specific developmental
clines. It is notable that ESCs have the largest DHS complement
of all cell types analyzed (n = 257,172 excluding ChrX/Y; Fig-
ure S3C and Table S1), of which 58% are shared with at least
one definitive cell type (Figure S3D).
Development along the hematopoietic lineage has been
extensively characterized at both the cellular and molecular
levels (Orkin, 1995). During hematopoiesis, the accessible chro-
matin landscape undergoes substantial reorganization that is
dominated by the inactivation rather than the de novo activation
of DHSs (Figures 3A and 3B). Comparison of the DHS landscape
of ESCs to that of hematopoietic progenitors reveals a net loss of
119,032 DHSs, achieved through the silencing of 202,412 ES
DHSs and the de novo activation of 83,380DHSs. As hematopoi-
etic progenitors terminally differentiate into B or T cells, they
preferentially inactivate a common set of72,000 early develop-
mental DHSs, while activating an average of 52,000 chiefly
lineage-restricted DHSs along each terminal branch (Figures
3C and 3D). Of note, roughly half of the regulatory DNA land-
scape of each definitive lymphoid cell type is retained from
hematopoietic progenitors and roughly one-third from ESCs
(Figure 3B).
Fixed Contribution of ES Regulatory DNA to Terminal
Regulatory Landscapes
We next asked how cells differ with respect to the proportion of
their regulatory landscapes shared with ESCs. The total number
of autosomal DHSs in definitive cell types varied >2-fold, from
91.7K in Th1 cells to 225.6K in dermal fibroblasts. Surprisingly,
within each cell-type landscape, the proportion of DHSs shared
with ESCs remained nearly constant, averaging 37% (Fig-
ure 3E). Of these, the vast majority were distal, nonpromoter
elements (Figure S3E). In total, across all cell types, approxi-
mately 56% of ES DHSs were retained in some definitive cells.
(Figure 3F). However, the specific complement of ES DHSs
apportioned to each cell type was unique (Figure 3F).
Regulatory Landscape Dynamics during Directed
Differentiation from ESCs
To analyze differentiating regulatory DNA landscape dynamics
prospectively, we next profiled DHSs during the controlled differ-
entiation of ESCs along the cardiac axis (Yang et al., 2008). Dur-
ing cardiac differentiation under defined conditions, committed
cardiac progenitors emerge at day 5 and beating cardiomyo-
cytes at day 14 (Paige et al., 2012). We produced DHS maps
for each of these stages (Table S2), as well as from adult heart
tissue (as ES-derived cardiomyocytes do not reach full maturity
and exhibit primitive features similar to those of early-fetal-stage
heart) (Paige et al., 2012).
During directed cardiac differentiation, we observed large-
scale reorganization of the DHS landscape (Figure 3G),
including inactivation of early developmental elements, exten-
sive forward propagation of ESC and progenitor DHSs, and
de novo activation of differentiation-stage-selective elements
(Figures 3H and 3I). The inactivation of ESC DHSs during differ-
entiation occurred in a progressive, nearly clock-like fashion,
dropping from 71% at day 5, to 49% at day 14, and 35% in
adult heart tissue (Figure 3J). Notably, the proportion of ESCDHSs in the terminally differentiated adult cardiac landscape
(35%) closely matches the average of other terminally differen-
tiated cells (37%; Figure 3E).
Together, the above findings indicate that the process of line-
age differentiation is accompanied by three basic alterations to
the regulatory DNA landscape: (1) pruning of ESC DHSs as a
function of developmental maturity (Figure 3K); (2) extensive for-
ward propagation of regulatory DNA from progenitors to more
defined cells (Figure 3L); and (3) de novo activation of a (generally
smaller) number of lineage-restricted DHSs (Figure 3L).
Patterning of Regulatory DNA by Known and Novel
Lineage Regulators
We reasoned that uncovering the TFs that interact with develop-
mentally dynamic (i.e., lost or gained) regulatory DNA should
facilitate identification of regulators of cellular identity. During
the transition from ESCs to hematopoietic progenitors, lost
DHSs were significantly enriched in recognition sequences for
pluripotency factors (OCT4, SOX2, NANOG), whereas gained
DHSswere enriched in recognition sequences for hematopoietic
master regulators including PU.1 and ELF1 (Orkin, 1995) (Fig-
ure 4A). By contrast, the subsequent transition from hematopoi-
etic progenitors to T cells, B cells, or NK cells results in selective
loss of DHSs enriched in hematopoietic master-regulator recog-
nition sequences and selective gain of DHSs enriched in major
T cell, B cell, or NK cell-lineage-regulator recognition sites,
respectively (Orkin, 1995) (Figures 4B and S4A). Notably, the
presence of TF recognition sequences in DHS peaks is highly
predictive of occupancy of the cognate TF, as measured using
ChIP-seq or genomic footprinting (Neph et al., 2012c; Samstein
et al., 2012). These results indicate that the TFs critical for a given
cell state can be identified through analysis of both DHSs lost
during transition away from that state and DHSs gained during
transition into that state.
Unlike hematopoietic development, few potent regulators
of cardiac differentiation have been characterized. Analysis of
the differentiation of ESCs to early cardiac progenitors (d5)
revealed selective loss of DHSs enriched in recognition sites
for pluripotency factors, coupled with gain of DHSs enriched
in motifs for both the well-described early cardiac regulator
PBX1 (Chang et al., 2008) and the novel cardiac regulator
MEIS2 (Paige et al., 2012) (Figure 4C, left). By contrast, the
subsequent transition from cardiac progenitors (d5) to early
cardiomyocytes (d14) featured loss of DHSs enriched in PBX1
recognition sites and the appearance of DHSs enriched in
binding elements for late cardiac regulators NKX2-5, NKX2-6,
and MEF2A (Lyons et al., 1995; Tanaka et al., 2001) (Figure 4C,
right).
The above analyses further implicated previously unrecog-
nized lineage-defining roles for numerous other TFs (Fig-
ure S4B). For example, the binding landscape for RREB1
contracts in every lineage except for hematopoietic progeni-
tors, where it expands (Figure S4B), indicating that this
repressor may play an important yet uncharacterized role in
hematopoiesis. Together, these findings indicate that regula-
tory DNA dynamics during specific developmental transitions
reflect the actions of both known and novel lineage-regulating
TFs (Figure 4D).Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc. 893
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Figure 3. Developmental Extinction, Maintenance, and De Novo Activation of Chromatin Accessibility at Regulatory DNA
(A and B) Composition of developing hematopoietic regulatory landscapes. (A) Shown are acquired (black) versus extinguished (red) DHSs during hematopoietic
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Coordinated Deactivation of Alternative Regulatory
Programs during Differentiation
We observed that recognition sites for TFs regulating a given
lineage were selectively enriched in the DHSs inactivated along
other lineage paths. For example, the recognition landscape
for the NK cell master regulator NFIL3 (Gascoyne et al., 2009)
remains largely unchanged during NK differentiation but greatly
contracts during T cell and B cell development (Figure 4E). Simi-
larly the regulatory landscape for the endothelial regulator
SOX17 (Liao et al., 2009) remains largely unchanged during
endothelial development but contracts during development of
all other lineages (Figure 4F). Similar lineage-restricted patterns
were observed for many factors including PU.1, RREB1, and
OCT4 (Figures 4F and S4B). This suggests that (1) the regulatory
DNA target landscape for certain lineage-restricted factors is
largely prepositioned in progenitor cell types via DHSs that
contain cognate binding elements and (2) such DHSs are selec-
tively inactivated along lineage paths in which the lineage-rele-
vant TF is lacking. Consequently, development according to a
specific lineage program combines the orchestrated activation
of lineage-restricted regulatory elements with programmed
extinction of regulatory DNA associated with alternative lineage
fates (Figure 7D). The latter should in turn serve to passively rein-
force lineage commitment.
‘‘Memory’’ DHSs Are Chiefly Occupied by TFs
that Regulate Their Own Expression
Many biological processes are perpetuated by reinforcing feed-
back loops. For example, TFs involved in autoregulatory feed-
back loops can stabilize their expression during cell division
and development (Ptashne et al., 1980; Alon, 2006).We therefore
asked whether developmentally stable DHSs were occupied by
TFs with autoregulatory features. Using TF-regulatory network
maps constructed from genomic footprinting of 23 of the
cell types studied here (Neph et al., 2012b), we identified, on
average, 68 simple autoregulating TFs per cell type (range
48–75) (Figure 5A). In every cell type analyzed, relative to devel-
opmentally dynamic DHSs, developmentally stable DHSs were
chiefly and preferentially populated with recognition sites for
these simple autoregulating TFs (Figures 5A, 5B, S5A, and
S5C), as well as TFs involved in two-node directed and three-
node directed loop-network architectures (Figures 5C–5F,
S5A, and S5C), which enable indirect autoregulatory behavior.
These findings were similar for both developmentally stable
distal and promoter-associated DHSs (Figures S5B and S5C).
Retrograde Remodeling of the Regulatory DNA
Landscape during Oncogenesis
We next explored how the DHS landscape reorganizes during a
major pathological deviation. We produced DHS maps from 21(G–J) Regulatory DNA landscape of cardiac differentiation. (G) Acquired (black)
illustrating the number of inherited versus gained DHSs during cardiac differentiati
value was calculated using the hypergeometric test. (J) Clock-like extinction of E
(K and L) The epigenetic landscape valley floor. (K) Differentiation is accompani
landscape (e.g., a narrowing of the epigenetic landscape’s valley floors) (gold).
accompanies differentiation.
See also Figure S3.diverse cancer cell lines plus purified sorted cells from two pri-
mary malignancies (two subtypes of acute myelogenous leuke-
mia arising in different unrelated individuals) (Figure 6A), yielding
between 74,292 and 209,903 autosomal DHSs per cancer cell
type (Table S3). We then used PCoA to compare the DHS land-
scapes of cancer cells with those of normal cells. Whereas the
regulatory DNA landscapes of normal cell types are clearly sepa-
rated (Figures 1C and 6B), cancer DHS landscapes converged
on those of ESCs (Figure 6B). Hematological malignancies
were a notable exception, forming a distinct group toward the
ESC facing pole of the hematopoietic lineage cluster (Figures
6B and S6A).
To quantify further the apparent retrograde remodeling of
cancer regulatory DNA landscapes, we focused our analysis
on four malignancies for which DHS maps were available
from the presumed corresponding normal precursor cell type
(melanocytes for melanoma; mammary epithelium for breast
cancer [two types]; and Th1 cells for T cell leukemia).
Compared with normal counterparts, all four cancer cell types
exhibited substantial reorganization of their DHS landscape in
a largely cell-specific manner (Figures 6C, 6D, S6B, and S6C).
This reorganization had three major components: (1) reactiva-
tion of silenced ESC DHSs (Figure 6E); (2) ectopic activation
of DHSs from lineage programs different than that in which
the malignancy arose; and (3) appearance of a small proportion
of novel DHSs not detected in any normal cell type. Overall, the
vast majority (88%–97%) of DHSs activated during oncogen-
esis were found in some other normal adult or fetal cell or tissue
type (Figure 6D). Notably, the regulatory DNA landscape acti-
vated during oncogenesis differed substantially between
different cancer cell types, with no DHS active in all cancer
cell types but no normal cell types (Figures 6C and S6C).
Together these results indicate that oncogenesis is character-
ized by the aberrant co-option of regulatory DNA from ESCs
and alternative lineage programs, with each cancer cell type
activating a distinct set of elements.
TF Drivers of Cancer Regulatory Landscapes
We next sought to identify TFs mediating reorganization of the
regulatory DNA landscape during oncogenesis. The ability of
many TFs to function as oncogenes or tumor suppressors is
well known (Persson and Leder, 1984). Analysis of DHSs
arising in cancers revealed significant enrichment of recogni-
tion sites for known oncogenic TFs. By contrast, DHSs
lost during oncogenesis were significantly enriched in recogni-
tion sequences for known tumor-suppressor TFs. For
example, the target landscape of FOXA1 specifically and
significantly expands in breast cancer cells compared with
normal breast epithelium (Figure 7A), consistent with the
role of FOXA1 in mediating estrogen-receptor-dependentversus extinguished (red) DHSs during cardiac differentiation. (H) Schematic
on. (I) Enrichment of ESCDHSswithin lost versus gained DHS compartments. p
SC DHSs during cardiac differentiation.
ed by the progressive restriction of the size of the accessible regulatory DNA
(L) Schematic showing restriction, perpetuation, and de novo activation that
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Figure 4. Selective Loss versus Gain of DHSs Targeted by Lineage Regulators
(A–C) Enrichment of lineage regulators in developmentally dynamic DHSs. Enrichment of binding elements for three pluripotency TFs (blue), eight hematopoietic
lineage and sublineage TFs (red/purple), and five cardiac lineage TFs (brown) in DHSs lost versus gained during (A) the differentiation of ESCs into hematopoietic
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landscape—paralleling Waddington’s regulatory genes and ‘‘guy-ropes’’ (Waddington, 1957).
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See also Figure S4.chromatin remodeling in breast cancer (Carroll et al., 2005).
Furthermore, the target landscape of SOX9 specifically and
significantly contracts in melanoma cells compared with
normal melanocytes, consistent with the role of SOX9 as a
potent melanoma tumor suppressor (Figure 7A) (Passeron896 Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc.et al., 2009). This analysis revealed a variety of TFs with similar
patterns of target landscape expansion or contraction in
normal versus tumor cells (Figures 7A and S7A), exposing po-
tential novel cell-selective oncogenic and tumor-suppressor
roles for such TFs.
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Figure 5. Epigenetically Stable DHSs Are Potentiated by TFs that Regulate Their Own Expression
(A) Enrichment of DNase I-footprinted binding elements for simple autoregulating TFs in developmentally stable (i.e., retained from ESCs) versus developmentally
gained DHSs in 20 cell types with annotated regulatory networks (Neph et al., 2012b).
(B) Enrichment of DNase I-footprinted binding elements for simple autoregulating TFs in developmentally stable DHSs retained from hematopoietic progenitors,
excluding sites retained from ESCs.
(C–F) Enrichment of DNase I-footprinted binding elements for TFs involved in two-node (C and D) or three-node (E and F) autoregulatory loops in developmentally
stable versus developmentally gained DHSs. All enrichments shown are significant (p < 1010, hypergeometric distribution).
See also Figure S5.Functionally Distorted Memory of Normal Lineage
Programs in Malignant Cells
Next we asked whether the transformed regulatory landscapes
of cancer cells maintained systematic memory of earlier devel-
opmental fate decisions, akin to normal cells (Figure 1).
Clustering 23 cancer cell types based on their DHS patterns
yielded well-defined clusters (Figure 7B). However, unlike those
seen in Figure 1 for normal cells, cancer DHS clusters were
typified by functional characteristics of the cancers, ratherthan their developmental origin For example, hormone-respon-
sive cancers (LNCap, T-47D, and MCF-7) formed a tight
cluster, distinct from those of other adult and pediatric solid
tumors, germ cell neoplasms, and hematological malignancies.
These findings suggest that oncogenic transformation of
the regulatory DNA landscape is accompanied by loss of
developmental information and can be dominated by selective
activation of regulatory elements associated with the derived
phenotype of the cancer.Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc. 897
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Figure 6. Retrograde Remodeling of the Regulatory DNA Landscape during Oncogenesis
(A) Developmental origins of 21 cancer cell lines and 2 primary cancers analyzed with genome-wide DNase I mapping.
(B) PCoA of normal versus malignant cell-type relationships. Shown are normal and cancer cell types projected into a three-dimensional principal coordinates
space. Cell-type coloring is indicated above. Note the prominent clustering of cancer cell types around ESCs (inset 1).
(C) Cell selectivity of cancer cell DHSs. Distribution of the number of cancer cell types in which (left) a DHS found in any cancer cell type is observed, (middle) a
DHS that is unique to cancer cell types and not found in any of the normal cell types is observed, and (right) a DHS shared between a cancer cell type and ESCs is
observed.
(D) Disordered retrograde remodeling of the accessible regulatory DNA landscape during oncogenesis. (D) Shown is the contribution of DHSs found in
nonmalignant predecessors to the DHS landscape of each of four cancer cell types. Cancer DHS landscapes are partitioned into DHSs originating in ESCs and
(legend continued on next page)
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Figure 7. TF Drivers, Functional Organization, and Evolutionary Pressures on Cancer Regulatory Landscapes
(A) Oncogenic versus tumor-suppressor TF targets in DHSs gained versus lost during oncogenesis. Shown is the enrichment of binding elements for four TF
oncogenes and three TF tumor suppressors in the DHSs lost versus gained during the oncogenic transformation of mammary epithelium and melanocytes.
(B) Functional reorientation of the malignant regulatory DNA landscape. Clustering of DHSs from 23 cancer cell types and three different ES lines. Note the
predominance of functional or phenotypic features over embryological origins.
(C) DHSs arising during oncogenesis show relaxed evolutionary constraint. Human nucleotide diversity measurements (p, y axis) at DHSs retained from
nonmalignant predecessors but not present in ESCs (blue); DHSs arising during oncogenesis that are ectopically activated from alternative lineages, excluding
ESCs (purple); and DHSs arising during oncogenesis that are novel to cancer (gray). Error bars represent 95% confidence intervals.
(D and E) Models of normal development and oncogenesis. Shown are the actions of different TF classes on the developing regulatory DNA landscape of
hematopoietic progenitors and endothelial cells (D) as well as the oncogenic transformation of mammary epithelium (E).
See also Figure S7.Reduced Evolutionary Pressure on Cancer Regulatory
Landscapes
Nucleotide diversity (pi) calculated with genomic sequence data
from multiple unrelated individuals provides a quantitative
assessment of the extent of ongoing purifying selection atmaintained in nonmalignant predecessors (blue), DHSs retained from nonmalign
arising during oncogenesis (gray). (Right) Proportion of DHSs arising during oncog
activated DHSs from alternative lineages (dark blue), or novel DHSs unique to ea
(E)Shown is theenrichmentofESCDHSswithin lost versusgainedDHScompartme
See also Figure S6 and Table S3.DHSs within the human population (Vernot et al., 2012; Thurman
et al., 2012; Neph et al., 2012c). To investigate whether DHSs
activated during oncogenesis exhibit levels of selective
constraint similar to normal developmentally patterned DHSs,
we calculated pi for these two classes of DHSs. Cancer cellant predecessors but not present in ESCs (purple/brown/orange), and DHSs
enesis that are reactivated (i.e., not inherited) ESCDHSs (light blue), ectopically
ch cancer cell type (gray).
ntsduringoncogenesis.p valueswerecalculatedusing thehypergeometric test.
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DHSs gained during oncogenesis evinced significantly higher
nucleotide diversity compared with those retained from normal
development (Figures 7C, S7B, and S7C). Of note, similar
numbers of DHSs are activated during both normal development
and oncogenesis (Figure 6D), yet elements activated during
oncogenesis are under less constraint, suggesting that cancer
cells selectively recruit regulatory elements that are active at
other developmental stages yet may play secondary roles in
normal developmental processes. Such reactivation events are
likely generated through dysregulation of key developmental
TFs (Figure 7A) and can have a large effect on the expression
of neighboring genes (Akhtar-Zaidi et al., 2012).
DISCUSSION
The salient findings recounted above can be recapitulated as fol-
lows: First, developmental fate and lineage relationships can be
derived from the genomic patterning of DHSs in definitive cells;
this patterning is distinct from the information conveyed by
gene expression. Second, lineage differentiation is associated
with three features: (1) extensive propagation of DNase I hyper-
sensitivity at regulatory DNA; (2) pruning of DHSs shared with
ESCs as development progresses; and (3) blossoming of a
smaller number of lineage-restricted DHSs—all resulting in a
more restricted, specialized DHS landscape. Third, pruning of
DHSs shared with ESCs during differentiation is proportional to
the size of a cell’s DHS landscape, with the result that the regu-
latory DNA landscapes of terminally differentiated cells retain a
nearly constant proportion of DHSs shared with ESCs. Fourth,
developmentally stable DHSs densely encode binding sites for
self-regulating TFs. Finally, in contrast to normal cells, cancer
regulatory landscapes feature both extensive reactivation of
silenced ESC DHSs and ectopic activation of regulatory DNA
from noncognate developmental lineages.
We interpret the above findings to signify a central role for DHS
patterning in propagating cellular state and fate information dur-
ing development and abrogation of this role by oncogenesis.
Below we place these findings in historical context and consider
both the features of differentiation that Waddington presaged as
well as a number of novel and telling insights that our results
afford into basic developmental mechanisms and strategies.
From Epigenesis to Epigenetics
The generation of consistent body plans by the sequential differ-
entiation of totipotential material is a foundational conceptual
paradigm for development. First articulated by Aristotle (De
generatione animalium 739a), this concept was termed ‘‘epigen-
esis’’ (literally, ‘‘moving toward coming into being’’) by Harvey
(Harvey, 1651) and was widely accepted by the early 20th
century (Patten, 1920). Waddington’s enduring epigenetic land-
scape paradigm crystallized this concept and added two impor-
tant features (Waddington, 1940, 1957). The first concerned the
stability of cellular phenotypes, which Waddington depicted as
the valley walls within the epigenetic landscape; these valley
walls act to guide the cell down a particular ‘‘pathway of change
that is equilibrated in the sense that the system tends to return to
it after disturbance’’ (Waddington, 1957). The second feature
was mechanistic: the proposition that the epigenetic landscape900 Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc.itself is controlled by a complex system of ‘‘regulatory genes’’
that interact with one another in a combinatorial and temporally
coordinated fashion to shape the topography of epigenesis
(Waddington, 1957).
In view of our results, Waddington’s paradigm provides a
remarkably prescient schematization of the transformation of
the regulatory DNA landscape during development, indicating
that global DHS maps provide a missing quantitative dimension
for major facets of epigenesis. The fact that proper lineage-
branching relationships can be recovered from DHS data but
not from gene-expression data suggests that the DHS com-
partment contains both elements involved in active cellular pro-
cesses as well as ‘‘marker’’ or ‘‘memory’’ DHSs that preserve
information about prior developmental states. Such information
is directly evident in persistent DHSs at tissue-selective early
developmental enhancers.
Role of TFs in Propagation of Active versus Repressive
Chromatin States
Our data indicate that changes in the DHS landscape during
development are orchestrated by specific combinations of line-
age-restricted TFs (Figure 4) and that developmentally stable
DHSs are chiefly occupied by autoregulatory TFs (Figure 5).
These results emphasize the central influence of the cellular
TF-regulatory network on modeling the regulatory DNA land-
scape during development (Figures 4D and 7D). It is notable
that other examples of ‘‘epigenetic memory’’ chiefly feature
propagation of repressive chromatin states through mecha-
nisms such as CpG methylation (Bird, 2002; Kim et al., 2010),
histone H3K9 trimethylation (Hathaway et al., 2012), or poly-
comb (Cavalli and Paro, 1998). Because TFs rapidly reassociate
with daughter DNA strands following replication and can book-
mark accessible regulatory DNA through mitosis (Egli et al.,
2008), TF binding within DHSs is mechanistically well-suited
for the propagation of accessible chromatin to daughter cells
without invoking other modifications to the chromatin template.
Developmental Transformation of the Regulatory DNA
Landscape
Development and differentiation, irrespective of lineage, balance
the propagation, extinction, and de novo activation of chromatin
accessibility at regulatory DNA in a highly formulaic manner.
During development, the regulatory DNA landscape undergoes
progressive restriction that outstrips the de novo activation
of lineage-restricted DHSs—metaphorically, a narrowing of the
epigenetic landscape’s valley floors (Figures 3K and 3L). Inter-
estingly, this process appears to be recursive, operating anew
from intermediate pluripotential states such as hematopoietic
stem cells in amanner reminiscent of classical finite state autom-
ata (Turing, 1937). Critically, selective DHS pruning involves the
wholesale loss of DHSs associated with alternative fates (Fig-
ure 4), thus cementing or ‘‘canalizing’’ a particular developmental
pathway in lockstep with differentiation.
Temporal ‘‘Memory’’ of Cellular State and Fate
A remarkable feature of the developmentally stable DHS
compartment is its association with cellular maturity. As cells
differentiate, ESC-originated DHSs are pruned in a progressive,
almost clock-like fashion. Consequently, simply measuring the
proportion of DHSs within a cell’s regulatory landscape that
are shared with ESCs may provide a quantitative measure of
developmental maturity.
Relation to the Developmental Hourglass
The concept that developmental biology can provide insights
into evolution was sparked by Von Baer’s observation that
embryos from diverse organisms converge on a common form
during the pharyngula stage of mid-embryogenesis (Von Baer,
1828). This point of convergence has been termed the ‘‘phylo-
typic’’ stage (Cohen, 1963) and coincides with the activation of
major developmental regulators such as Hox genes (Duboule,
1994). These observations gave rise to an hourglass model of
development (Duboule, 1994; Raff, 1996). Our data in Figure 1D
accord with this model and indicate that the hourglass phenom-
enon may be grounded within discrete sets of regulatory DNA
regions.
Connecting Epigenesis and Oncogenesis
Oncogenesis is accompanied by the drastic remodeling of
the DHS landscape, resulting in a loss of developmental infor-
mation, and reversion to a ‘‘pseudoprimitive’’ state that
combines regulatory DNA features of ESCs with those of other
developing lineages (Figures 6 and 7). This state is not truly
de-differentiated—which implies walking back along a path pre-
viously taken—but rather dys-differentiated, having aberrantly
co-opted ‘‘normal’’ regulatory elements from alternative lineage
paths (Figure 7E). As such, cancer cells encompass a multi-
dimensional deviation from normal development and can no
longer be placed on Waddington’s landscape. This feature
may explain the long-standing observation that oncogenesis is
accompanied by the reappearance of fetal antigens (Hirszfeld
et al., 1932; Tatarinov, 1964). Notably, this finding is difficult to
reconcile with models of oncogenesis that posit cancer origins
from developmental remnants. If cancer cells simply arose
from uncontrolled proliferation of a more primitive cell remnant,
we would expect cancer cells to retain strong lineage signa-
tures; however, with the exception of hematological malig-
nancies, this is decidedly not the case.
The process of dys-differentiation appears to result from the
misregulation of key developmental TFs (Figure 7A). However,
despite the growth and phenotypic advantages bestowed by
the transformed regulatory DNA landscape, malignant cells
have likely lost many of the beneficial regulatory redundancies
and feedback mechanisms that are formed during normal devel-
opment and that maintain epigenetic stability in the face of envi-
ronmental and genetic stress (Figures 7D and 7E). It is tempting
to speculate that this patchwork reorganization of the chromatin
landscape during oncogenesis may expose exploitable vulnera-
bilities of the malignant state.
EXPERIMENTAL PROCEDURES
DHS Mapping
All cell types were subjected to nuclear isolation, DNase I digestion, DNase I
double-hit fragment purification and library construction, and high-throughput
sequencing, as described previously (Thurman et al., 2012; John et al., 2011;Hesselberth et al., 2009). Data from additional cell types were utilized from
Thurman et al. (2012). DHSs were computed for each cell type at an FDR of
1% as previously described (John et al., 2011).
DHS Clustering
We used the BEDOPS suite to generate a reference multiset union of DHSs
across all cell types (Neph et al., 2012a). The Euclidean distance between
two cell types was calculated using binary peak calls for each DHS within
the reference set for a given cell type. Pairwise Euclidean distances between
all cell types were clustered using the nearest-neighbor algorithm. For cancer
cell types, we utilized Euclidean distances and Ward clustering.
Comparison of Adult versus Embryonic Enhancer Activity
Data for tests of human enhancers in a mouse developmental model (Pennac-
chio et al., 2006) were downloaded from http://enhancer.lbl.gov/.
Autoregulating TFs
Comprehensive maps of human TF-regulatory networks constructed with
genome-wide DNase I footprint maps were used to identify TFs that form
autoregulatory loops (Neph et al., 2012b). The occupancy of these autoregu-
latory TFs within developmentally stable and developmentally gained DHSs
was mapped using TF-binding elements contained within DNase I footprints
(Neph et al., 2012c).
Human Nucleotide Diversity Measurements
Human nucleotide diversity measurements (p) were calculated using whole-
genome sequences from 53 unrelated individuals as previously described
(Vernot et al., 2012).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and three tables and can be found with this article online at http://dx.
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ACKNOWLEDGMENTS
This work was supported by NIH grants U54HG004592, U54HG007010, and
U01ES017156 to J.A.S.; NIH grant P30DK056465 to S.H.; and NIH grants
P01GM081719, U01HL100405, P01HL094374, and R01HL084642 to C.E.M.
We thank many colleagues, particularly Joseph Costello (UCSF), for contrib-
uting cells for DNase I mapping and expression profiling. A.B.S. was sup-
ported by grant FDK095678A from NIDDK. S.L.P. was supported by NHLBI
grant F30HL095343. We thank Rae Senarighi (UW) for expert assistance
with graphic design. All data from this study are available through the ENCODE
data repository at UCSC (http://www.encodeproject.org) and the Roadmap
Epigenomics data repository at NCBI (http://www.ncbi.nlm.nih.gov/
epigenomics). All data from this study are free to use and are not subject to
consortium embargo dates.
Received: February 13, 2013
Revised: April 16, 2013
Accepted: July 12, 2013
Published: August 15, 2013
REFERENCES
Akhtar-Zaidi, B., Cowper-Sal-lari, R., Corradin, O., Saiakhova, A., Bartels,
C.F., Balasubramanian, D., Myeroff, L., Lutterbaugh, J., Jarrar, A., Kalady,
M.F., et al. (2012). Epigenomic enhancer profiling defines a signature of colon
cancer. Science 336, 736–739.
Alon, U. (2006). An Introduction to Systems Biology: Design Principles of
Biological Circuits, First Edition (London: Chapman and Hall/CRC).
Bard, J., Rhee, S.Y., and Ashburner, M. (2005). An ontology for cell types.
Genome Biol. 6, R21.Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc. 901
Beard, J. (1902). Embryological aspects and etiology of carcinoma. Lancet
159, 1758–1761.
Bernstein,B.E.,Mikkelsen,T.S.,Xie,X.,Kamal,M.,Huebert,D.J.,Cuff, J., Fry,B.,
Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin structure
marks key developmental genes in embryonic stem cells. Cell 125, 315–326.
Bird, A. (2002). DNAmethylation patterns and epigenetic memory. Genes Dev.
16, 6–21.
Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J.,
Eeckhoute, J., Shao, W., Hestermann, E.V., Geistlinger, T.R., et al. (2005).
Chromosome-wide mapping of estrogen receptor binding reveals long-range
regulation requiring the forkhead protein FoxA1. Cell 122, 33–43.
Cavalli, G., and Paro, R. (1998). The Drosophila Fab-7 chromosomal element
conveys epigenetic inheritance during mitosis and meiosis. Cell 93, 505–518.
Chang, C.-P., Stankunas, K., Shang, C., Kao, S.-C., Twu, K.Y., and Cleary,
M.L. (2008). Pbx1 functions in distinct regulatory networks to pattern the great
arteries and cardiac outflow tract. Development 135, 3577–3586.
Cohen, J. (1963). Living Embryos: An Introduction to the Study of Animal
Development (New York: Pergamon Press).
Domazet-Loso, T., and Tautz, D. (2010). A phylogenetically based transcrip-
tome age index mirrors ontogenetic divergence patterns. Nature 468,
815–818.
Duboule, D. (1994). Temporal colinearity and the phylotypic progression: a
basis for the stability of a vertebrate Bauplan and the evolution of morphol-
ogies through heterochrony. Dev. Suppl. 1994, 135–142.
Egli, D., Birkhoff, G., and Eggan, K. (2008). Mediators of reprogramming: tran-
scription factors and transitions through mitosis. Nat. Rev. Mol. Cell Biol. 9,
505–516.
Gascoyne, D.M., Long, E., Veiga-Fernandes, H., de Boer, J.,Williams, O., Sed-
don, B., Coles, M., Kioussis, D., and Brady, H.J.M. (2009). The basic leucine
zipper transcription factor E4BP4 is essential for natural killer cell develop-
ment. Nat. Immunol. 10, 1118–1124.
Gleason, D.F., and Mellinger, G.T. (1974). Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging.
J. Urol. 111, 58–64.
Gross, D.S., and Garrard, W.T. (1988). Nuclease hypersensitive sites in
chromatin. Annu. Rev. Biochem. 57, 159–197.
Groudine, M., and Weintraub, H. (1982). Propagation of globin DNAase
I-hypersensitive sites in absence of factors required for induction: a possible
mechanism for determination. Cell 30, 131–139.
Harvey, W. (1651). Exercitationes de Generatione Animalium (London: Typis
Du-Gardianis; Impensis O. Pulleyn).
Hathaway, N.A., Bell, O., Hodges, C., Miller, E.L., Neel, D.S., and Crabtree,
G.R. (2012). Dynamics and memory of heterochromatin in living cells. Cell
149, 1447–1460.
Hawkins, R.D., Hon, G.C., Lee, L.K., Ngo, Q., Lister, R., Pelizzola, M., Edsall,
L.E., Kuan, S., Luu, Y., Klugman, S., et al. (2010). Distinct epigenomic land-
scapes of pluripotent and lineage-committed human cells. Cell Stem Cell 6,
479–491.
Hesselberth, J.R., Chen, X., Zhang, Z., Sabo, P.J., Sandstrom, R., Reynolds,
A.P., Thurman, R.E., Neph, S., Kuehn, M.S., Noble, W.S., et al. (2009). Global
mapping of protein-DNA interactions in vivo by digital genomic footprinting.
Nat. Methods 6, 283–289.
Hirszfeld, L., Halber, W., and Rosenblat, J. (1932). Untersuchungen uber
Verwandtschaftsreaktionen zwischen embryonal und Krebsgewebe. II.
Menschenembryo und Menschenkrebs. ZeitschriftfUr Immunitatsforschung
und Experimentelle Therapie 75, 209–216.
John, S., Sabo, P.J., Thurman, R.E., Sung, M.-H.H., Biddie, S.C., Johnson,
T.A., Hager, G.L., and Stamatoyannopoulos, J.A. (2011). Chromatin accessi-
bility pre-determines glucocorticoid receptor binding patterns. Nat. Genet.
43, 264–268.
Kalinka, A.T., Varga, K.M., Gerrard, D.T., Preibisch, S., Corcoran, D.L., Jarrells,
J., Ohler, U., Bergman, C.M., and Tomancak, P. (2010). Gene expression902 Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc.divergence recapitulates the developmental hourglass model. Nature 468,
811–814.
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji,
H., Ehrlich, L.I.R., et al. (2010). Epigenetic memory in induced pluripotent stem
cells. Nature 467, 285–290.
Liao, W.P., Uetzmann, L., Burtscher, I., and Lickert, H. (2009). Generation of a
mouse line expressing Sox17-driven Cre recombinase with specific activity in
arteries. Genesis 47, 476–483.
Lyons, I., Parsons, L.M., Hartley, L., Li, R., Andrews, J.E., Robb, L., and
Harvey, R.P. (1995). Myogenic and morphogenetic defects in the heart tubes
of murine embryos lacking the homeo box gene Nkx2-5. Genes Dev. 9,
1654–1666.
Morgan, T.H. (1901). Regeneration in the egg, embryo, and adult. Am. Nat. 35,
949–973.
Neph, S., Kuehn, M.S., Reynolds, A.P., Haugen, E., Thurman, R.E., Johnson,
A.K., Rynes, E., Maurano, M.T., Vierstra, J., Thomas, S., et al. (2012a).
BEDOPS: high-performance genomic feature operations. Bioinformatics 28,
1919–1920.
Neph, S., Stergachis, A.B., Reynolds, A., Sandstrom, R., Borenstein, E., and
Stamatoyannopoulos, J.A. (2012b). Circuitry and dynamics of human tran-
scription factor regulatory networks. Cell 150, 1274–1286.
Neph, S., Vierstra, J., Stergachis, A.B., Reynolds, A.P., Haugen, E., Vernot, B.,
Thurman, R.E., John, S., Sandstrom, R., Johnson, A.K., et al. (2012c). An
expansive human regulatory lexicon encoded in transcription factor footprints.
Nature 489, 83–90.
Orkin, S.H. (1995). Transcription factors and hematopoietic development.
J. Biol. Chem. 270, 4955–4958.
Paige, S.L., Thomas, S., Stoick-Cooper, C.L., Wang, H., Maves, L., Sand-
strom, R., Pabon, L., Reinecke, H., Pratt, G., Keller, G., et al. (2012). A temporal
chromatin signature in human embryonic stem cells identifies regulators of
cardiac development. Cell 151, 221–232.
Passeron, T., Valencia, J.C., Namiki, T., Vieira, W.D., Passeron, H., Miyamura,
Y., and Hearing, V.J. (2009). Upregulation of SOX9 inhibits the growth of
human and mouse melanomas and restores their sensitivity to retinoic acid.
J. Clin. Invest. 119, 954–963.
Patten, B. (1920). The Early Embryology of the Chick (Philadelphia: P. Blakis-
ton’s Son & Co. Inc.).
Pennacchio, L.A., Ahituv, N., Moses, A.M., Prabhakar, S., Nobrega, M.A.,
Shoukry, M., Minovitsky, S., Dubchak, I., Holt, A., Lewis, K.D., et al. (2006).
In vivo enhancer analysis of human conserved non-coding sequences. Nature
444, 499–502.
Persson, H., and Leder, P. (1984). Nuclear localization and DNA binding
properties of a protein expressed by human c-myc oncogene. Science 225,
718–721.
Ptashne, M. (2007). On the use of the word ‘epigenetic’. Curr. Biol. 17, R233–
R236.
Ptashne, M., Jeffrey, A., Johnson, A.D., Maurer, R., Meyer, B.J., Pabo, C.O.,
Roberts, T.M., and Sauer, R.T. (1980). How the lambda repressor and cro
work. Cell 19, 1–11.
Pujadas, E., and Feinberg, A.P. (2012). Regulated noise in the epigenetic land-
scape of development and disease. Cell 148, 1123–1131.
Raff, R.A. (1996). The Shape of Life: Genes, Development, and the Evolution of
Animal Form (Chicago, IL: University of Chicago Press).
Samstein, R.M., Arvey, A., Josefowicz, S.Z., Peng, X., Reynolds, A., Sand-
strom, R., Neph, S., Sabo, P., Kim, J.M., Liao, W., et al. (2012). Foxp3 exploits
a pre-existent enhancer landscape for regulatory T cell lineage specification.
Cell 151, 153–166.
Tanaka, M., Schinke, M., Liao, H.S., Yamasaki, N., and Izumo, S. (2001).
Nkx2.5 and Nkx2.6, homologs of Drosophila tinman, are required for develop-
ment of the pharynx. Mol. Cell. Biol. 21, 4391–4398.
Tatarinov, IuS. (1964). Detection of embryo-specific alpha-globulin in
the blood serum of a patient with primary liver cancer. Vopr. Med. Khim. 10,
90–91.
Thurman, R.E., Rynes, E., Humbert, R., Vierstra, J.,Maurano,M.T., Haugen, E.,
Sheffield, N.C., Stergachis, A.B., Wang, H., Vernot, B., et al. (2012).
Theaccessible chromatin landscapeof thehumangenome.Nature 489, 75–82.
Turing, A.M. (1937). On computable numbers, with an application to the
entscheidungs problem. Proc. Lond. Math. Soc. 42, 230–265.
Vernot, B., Stergachis, A.B., Maurano, M.T., Vierstra, J., Neph, S., Thurman,
R.E., Stamatoyannopoulos, J.A., and Akey, J.M. (2012). Personal and popula-
tion genomics of human regulatory variation. Genome Res. 22, 1689–1697.
Von Baer, K.E. (1828). U¨ber Entwicklungsgeschichte der Thiere. Beobachtung
und Reflexion (Ko¨nigsberg: Gebru¨der Borntra¨ger).
Waddington, C.H. (1935). Cancer and the theory of organiser. Nature 135,
606–608.
Waddington, C.H. (1939). An Introduction to Modern Genetics (New York: The
Macmillan Company).Waddington, C.H. (1940). Organisers and Genes (Cambridge, UK: Cambridge
University Press).
Waddington, C.H. (1957). The Strategy of the Genes: A Discussion of Some
Aspects of Theoretical Biology (Sydney: George Allen & Unwin).
Wamstad, J.A., Alexander, J.M., Truty, R.M., Shrikumar, A., Li, F., Eilertson,
K.E., Ding, H., Wylie, J.N., Pico, A.R., Capra, J.A., et al. (2012). Dynamic and
coordinated epigenetic regulation of developmental transitions in the cardiac
lineage. Cell 151, 206–220.
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309–314.
Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy,
M., Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al. (2008).
Human cardiovascular progenitor cells develop from a KDR+ embryonic-
stem-cell-derived population. Nature 453, 524–528.
Zhu, J., Adli, M., Zou, J.Y., Verstappen, G., Coyne, M., Zhang, X., Durham, T.,
Miri, M., Deshpande, V., De Jager, P.L., et al. (2013). Genome-wide chromatin
state transitions associated with developmental and environmental cues. Cell
152, 642–654.Cell 154, 888–903, August 15, 2013 ª2013 Elsevier Inc. 903
